A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects

被引：0
|
作者：
Pirner, Mark A.
Lin, Jing
Liu, Feng
Yao, Lili
Zettler, Marjorie E.
Valacer, David J.
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-724-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
724-P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] RGT-075, an Orally Efficacious Small Molecule GLP-1R Full Agonist in Cynomolgus Monkey Models
    Liu, Feng
    Sun, Xianqiang
    Huang, Wei
    Guo, Wei
    Lin, Jing
    Zhong, Wenge
    DIABETES, 2022, 71
  • [2] A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes
    Pirner, Mark A.
    Lin, Jing
    Liu, Feng
    Yao, Lili
    Zettler, Marjorie E.
    Valacer, David J.
    DIABETES, 2022, 71
  • [3] A First-in-Human Single Ascending Dose Study of GSBR-1290, a Novel Small Molecule GLP-1 Receptor Agonist, in Healthy Volunteers
    Coll, Blai
    Zhang, Jinqiang J.
    Jacober, Scott J.
    Argent, Christopher
    Ibarra, Lani
    Snyder, Margo
    Bach, Mark A.
    DIABETES, 2023, 72
  • [4] Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects
    Urva, Shweta
    Du, Yu
    Thomas, Melissa K.
    Milicevic, Zvonko
    Coskun, Tamer
    Benson, Charles
    Loghin, Corina
    DIABETES, 2021, 70
  • [5] Novel GIP/GLP-1/glucagon receptor agonist LY3437943: a first in human dose study in healthy subjects
    Benson, C. T.
    Loghin, C.
    Du, Y.
    Thomas, M. K.
    Coskun, T.
    Urva, S.
    Milicevic, Z.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 116 - 116
  • [6] Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist
    Haggag, Amina Z.
    Xu, Jianfeng
    Butcher, Laurie
    Pagnussat, Sandra
    Davies, Graeme
    Lundqvist, Sara
    Wang, Wenyu
    Van Zuydam, Natalie
    Nelander, Karin
    Jha, Aruni
    Yu, Hongtao
    Boianelli, Alessandro
    Lindmark, Bosse
    Ollerstam, Anna
    Sun, Xuefeng
    Wang, Fan
    Pan, Xiaoliang
    Liu, Haihui
    Chen, Wengang
    Xu, Jianfeng
    Wallenius, Kristina
    Zhou, Jingye
    DIABETES OBESITY & METABOLISM, 2025, 27 (02): : 551 - 562
  • [7] Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel oral small molecule GLP-1 receptor agonist (HRS-7535) in healthy subjects
    Wu, J.
    Hu, W.
    Du, Y.
    Zhang, Q.
    Zhou, R.
    Zhang, Q.
    Qin, H.
    Ye, Z.
    Xu, Y.
    Feng, S.
    Shu, C.
    Shen, Y.
    Fan, Y.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S316 - S317
  • [8] Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist
    Mao, Ting
    Meng, Qinghua
    Zhang, Haizhen
    Zhang, Jinqiang J.
    Shi, Songting
    Guan, Zhibo
    Jiang, Xinglong
    Zhang, Fang
    Lei, Hui
    Lin, Xichen
    DIABETES, 2023, 72
  • [9] A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
    Pratt, Edward J.
    Ma, Xiaosu
    Liu, Rong
    Robins, Deborah A.
    Sloop, Kyle
    Benson, Charles
    DIABETES, 2022, 71
  • [10] First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
    Zhang, Hong
    Li, Qianqian
    Chen, Hong
    Guo, Lingfeng
    Li, Jing
    Xie, Can
    Yan, Jiangyu
    Ding, Yanhua
    BIODRUGS, 2025, : 477 - 486
12345